Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
Trial details
- Registry ID
- NCT00589875
- Phase
- Phase 2
The FDA approved Temozolomide (TMZ) on 11 Aug 1999.
Drug identity checked against registry records
Also recorded as TMZ; Temodar
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaNCT00589875 | CADL | Phase 2 | Completed | 2015-12Actual |
| ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeNCT04587830 | Polaris Group | Phase 2 | Active not recruiting | 2027-02-28Estimated |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)NCT06346067 | ERAS | Phase 3 | Active not recruiting | 2028-04Estimated |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaNCT06556563 | NovoCure GmbH | Phase 3 | Active not recruiting | 2029-04Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1999-08-11Day | Temozolomide | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021029", "applicant_as_listed_by_fda": "MERCK SHARP DOHME", "brand_names": ["TEMODAR"], "active_ingredients": ["TEMOZOLOMIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19990811", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |